Table 3.
Effects of first-line and second-line treatments in NSCLC (67).
| Overall Population | EGFR mutation | KRAS mutation | BRAF mutation | HER2 mutation | PIK3CA mutation | ALK rearrangement | Full WT | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 17664) | (n = 1,787) | (n = 4,588) | (n = 230) | (n = 92) | (n = 157) | (n = 340) | (n = 2,769) | |||||||
| All | Adapted$ | All | Adapted$ | All | Adapted$ | All | Adapted$ | All | Adapted$ | All | Adapted$ | All | ||
| First-line Treatment | ||||||||||||||
| Number with data % | 8,448 (48%) | 1,128 (63%) | 662 (37%) | 2,085 (45%) | 979 (21%) | 146 (64%) | 64 (28%) | 62 (67%) | 28 (30%) | 73 (47%) | 29 (19%) | 236 (69%) | 120 (35%) | 1,214 (44%) |
| Pemetrexed-based regimen | 2,747 (33%) | 188 (17%) | 57 (9%) | 792 (38%) | 525 (54%) | 51 (35%) | 34 (53%) | 31 (50%) | 18 (64%) | 17 (23%) | 11 (38%) | 111 (47%) | 55 (46%) | 401 (33%) |
| Vinorelbine-based regimen | 504 (6%) | 39 (3%) | 9 (1%) | 128 (6%) | 68 (7%) | 5 (4%) | 2 (3%) | 0 | 0 | 7 (10%) | 3 (10%) | 13 (6%) | 9 (8%) | 80 (7%) |
| Taxane-based regimen | 1,064 (13%) | 60 (5%) | 18 (3%) | 261 (13%) | 166 (17%) | 20 (14%) | 12 (19%) | 8 (13%) | 4 (14%) | 11 (15%) | 7 (24%) | 17 (7%) | 11 (9%) | 188 (16%) |
| EGFR-TKI | 684 (8%) | 543 (48%) | 520 (79%) | 26 (1%) | 9 (1%)* | 3 (2%)* | 2 (3%)* | 0 | 0 | 1 (1%)* | 1 (3%)* | 4 (2%)* | 2 (12%)* | 17 (1%) |
| Crizotinib | 18 (<1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 (8%) | 18 (15%) | 0 |
| Trial£ | 253 (3%) | 36 (3%) | 31 (5%) | 63 (3%) | 48 (5%) | 8 (6%) | 5 (8%) | 3 (5%) | 1 (4%) | 0 | 0 | 16 (7%) | 12 (10%) | 36 (3%) |
| Other§ | 709 (8%) | 27 (2%) | 9 (1%) | 171 (8%) | 77 (8%) | 11 (8%) | 3 (5%) | 5 (8%) | 3 (11%) | 10 (14%) | 5 (17%) | 6 (3%) | 3 (4%) | 131 (11%) |
| BSC only | 2,469 (29%) | 235 (21%) | 18 (3%) | 644 (31%) | 86 (9%) | 48 (33%) | 6 (9%) | 15 (24%) | 2 (7%) | 27 (37%) | 2 (7%) | 51 (22%) | 10 (8%) | 361 (30%) |
| Second-line Treatment | ||||||||||||||
| Number with data % | 5,518 (31%) | 698 (39%) | 381 (21%) | 1,358 (30%) | 566 (12%) | 106 (46%) | 37 (16%) | 43 (47%) | 22 (24%) | 48 (34%) | 12 (8%) | 157 (46%) | 102 (30%) | 797 (29%) |
| Taxane | 782 (14%) | 46 (7%) | 34 (9%) | 236 (17%) | 203 (36%) | 16 (15%) | 8 (22%) | 6 (14%) | 4 (18%) | 5 (10%) | 2 (17%) | 5 (3%) | 4 (4%) | 119 (15%) |
| Pemetrexed | 612 (11%) | 125 (18%) | 97 (26%) | 136 (10%) | 105 (19%) | 8 (8%) | 6 (16%) | 5 (12%) | 4 (18%) | 4 (8%) | 2 (17%) | 13 (8%) | 10 (10%) | 81 (10%) |
| Erlotinib | 776 (14%) | 231 (33%) | 218 (57%) | 125 (9%) | 94 (17%) | 9 (9%) | 4 (11%) | 5 (12%) | 4 (18%) | 2 (4%) | 2 (17%) | 10 (6%) | 6 (6%) | 96 (12%) |
| Crizotinib | 73 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 73 (46%) | 73 (72%) | 0 |
| Trial£ | 116 (2%) | 8 (1%) | 7 (2%) | 33 (2%) | 27 (5%) | 5 (5%) | 5 (14%) | 3 (7%) | 2 (9%) | 2 (4%) | 1 (8%) | 4 (3%) | 4 (4%) | 25 (3%) |
| Other§ | 442 (8%) | 10 (1%) | 6 (2%) | 90 (7%) | 60 (11%) | 8 (8%) | 7 (19%) | 8 (18%) | 8 (36%) | 2 (4%) | 2 (17%) | 5 (3%) | 3 (3%) | 79 (10%) |
| BSC only | 2,711 (49%) | 272 (39%) | 15 (4%) | 738 (54%) | 77 (14%) | 60 (57%) | 7 (19%) | 16 (37%) | 0 | 33 (69%) | 3 (25%) | 47 (30%) | 2 (2%) | 397 (50%) |
*: Patients with tumors exhibited two molecular alterations including EGFR mutation. $: Selection of treatment based on the molecular analyses. £: Based on targeted therapy.
§: Including, but not limited to, another type of chemotherapy.